Related Experiment Video
Updated: Jun 22, 2025
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Use of Fludrocortisone for Hyperkalemia in Chronic Kidney Disease Not Yet on Dialysis
Eun Kyoung Lee1, Won Seok Yang2
1Division of Nephrology, Department of Internal Medicine, Dankook University Hospital, Dankook University College of Medicine, Cheonan, Republic of Korea.
Insights
Low-dose fludrocortisone effectively lowers potassium in chronic kidney disease (CKD) patients before dialysis. However, this treatment can cause sodium retention and related adverse effects.
Area of Science:
- Nephrology
- Internal Medicine
- Pharmacology
Background:
- Hyperkalemia is a serious complication in chronic kidney disease (CKD).
- Managing hyperkalemia in pre-dialysis CKD patients is crucial.
- Oral fludrocortisone is explored for its potassium-lowering effects.
Purpose of the Study:
- To evaluate the efficacy of oral fludrocortisone in reducing serum potassium levels.
- To assess the adverse effects, particularly sodium retention, associated with fludrocortisone treatment.
- To investigate fludrocortisone's role in hyperkalemic CKD patients not yet on dialysis.
Main Methods:
- Retrospective study of 33 hyperkalemic CKD patients not on dialysis.
- Patients received low-dose fludrocortisone (0.05-0.1 mg/day).
- Two groups were analyzed: one with continued use of ARBs/CPS, another with adjustments to these medications.
Main Results:
- Serum potassium significantly decreased in both treatment groups (p<0.001).
- The frequency of severe hyperkalemia (≥6.0 mEq/L) dropped substantially in both groups (p<0.001).
- Eleven patients experienced adverse events related to sodium retention, including edema and effusions.
Conclusions:
- Low-dose fludrocortisone is effective in lowering serum potassium in pre-dialysis CKD patients.
- Sodium retention is a common adverse effect requiring monitoring.
- Fludrocortisone offers a viable option for managing hyperkalemia in this patient population.
Background:
Hyperkalemia is a frequent and potentially lethal complication of chronic kidney disease (CKD). We retrospectively examined the potassium-lowering effect of oral fludrocortisone and its adverse effects in hyperkalemic CKD patients not yet on dialysis.
Methods:
Thirty-three patients (23 men and 10 women, ages 69±14 years) were included. To control hyperkalemia at the outpatient clinic, twenty-one patients (Group 1) received fludrocortisone (0.05-0.1 mg/day) without changes in angiotensin II receptor blockers (ARBs) and calcium polystyrene sulfonate (CPS), while twelve patients (Group 2) were treated with fludrocortisone in addition to stopping ARBs and/or adding low-dose CPS.
Results:
Fludrocortisone was administered for a median of 169 days (interquartile range, 47-445). At the first follow-up after fludrocortisone administration, serum potassium dropped from 6.14±0.32 mEq/L to 4.52±1.06 mEq/L (p<0.001) in Group 1 and from 6.37±0.35 mEq/L to 4.08±0.74 mEq/L (p<0.01) in Group 2. Ten patients in Group 1 and five patients in Group 2 measured serum potassium levels at four outpatient visits before and after fludrocortisone administration, respectively. The frequency of serum potassium ≥6.0 mEq/L decreased from 19/40 (48%) to 2/40 (5%) (p<0.001) in Group 1 and from 11/20 (55%) to 0/20 (0%) (p<0.001) in Group 2. Eleven patients experienced sodium retention-related problems after fludrocortisone administration: 7 with worsening leg edema, 2 with pleural effusions, and 2 with pulmonary edema.
Conclusion:
In pre-dialysis CKD patients, fludrocortisone at low doses effectively reduced serum potassium levels; however, sodium retention was a common adverse effect.
Related Concept Videos
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
01:22Heart Failure Drugs: Diuretics
01:11Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
01:28Renal Drug Excretion: Tubular Secretion
01:15Renal Drug Excretion: Overview
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules...
01:25Renal Drug Excretion: Tubular Reabsorption